Vancouver, British Columbia–(Newsfile Corp. – May 1, 2026) – Adaptogenics Health Corp. (CSE): : ADPT) (“Adaptogenics“, “company“) has announced that its Board of Directors has launched a strategic review to evaluate potential business opportunities within the broader health and wellness sector.
As part of this review, the Company’s Board of Directors and senior management are examining a range of potential strategic initiatives, which may include potential business line changes, strategic partnerships, acquisitions, divestitures, capital markets activities, or other strategic actions designed to evaluate opportunities to support the Company’s long-term strategy and positioning within the evolving health and wellness markets.
The purpose of the strategic review is to assess whether alignment with emerging trends, technologies and consumer demand in the health, nutrition and wellness sector can support the company’s long-term strategic objectives. The Company is also evaluating whether repositioning, expansion or development of new product platforms or distribution strategies in the Canadian market and selected international markets is feasible and commercially viable.
No decisions have been made at this time to pursue any transaction, restructuring, business transformation or other strategic initiative. There can be no assurance that the strategic review will result in any specific results, recommendations or changes to the Company’s current operations. The Company has not established any timetable for completing the review and does not intend to comment further until required under applicable Canadian securities laws, including National Instrument 51-102 – Continuous Disclosure ObligationNational Policy 51-201 – disclosure standardsor the policies of the Canadian Securities Exchange.
management change
The company has also announced the appointment of Anthony Franco as Director and Chief Executive Officer of the company.
Mr. Franco is an experienced operations and strategy executive with over 20 years of experience in the legal, technology and biotech industries. He holds a bachelor’s degree in business management from Southern Connecticut State University and a Juris Doctorate from Western New England School of Law. They have an established track record helping organizations define the way they work, develop their strategy and achieve their corporate goals. Most recently, he served as General Manager of ReST Therapeutics, a neuropsychiatric startup developing therapies for PTSD, Alzheimer’s, and traumatic brain injury. Mr. Franco was also Chief Operating Officer of Infinite Health, where he was responsible for operational transformation within its consumer supplements division and establishing a pharmaceutical development program focused on rare pediatric diseases. A decade ago, he held a number of rising leadership positions at Alexion Pharmaceuticals in product development, global operations, corporate real estate and IT, until its acquisition by AstraZeneca. Early in his career, he also ran a successful legal practice focused on corporate real estate and business law.
